Gilead Sciences, Inc.

- Gilead does not expect sizable M&A in the near term, indicating limited need for major fundraising through large deals. - The company has about $5 billion in cash and leverage levels back to pre-Immunomedics acquisition, providing substantial financial flexibility. - Near-term capital deployment will focus on ordinary corporate development and licensing deals rather than meaningful M&A. - Gilead remains disciplined in capital use, continuing to invest in its pipeline and organic growth. - There is no explicit mention in the call transcript of plans for new fundraising through equity or debt at this time. - The firm is focused on maintaining disciplined expense management and expects to manage within current financial resources.

- Gilead plans to double manufacturing capacity for its cell therapy franchise, as outlined at the recent Kite analyst event. - The company is advancing next-generation CAR-T products with fast manufacturing processes (e.g., 3-day manufacturing). - Gilead intends to make incremental investments to support the launch of the newly acquired seladelpar and ongoing R&D activities. - The company expects to operate with disciplined capital allocation, focusing on pipeline investments and ordinary corporate development/licensing. - In the near term, Gilead does not anticipate sizable M&A but is open to doing smaller deals regularly over the cycle, similar to the CymaBay acquisition. - Gilead is prioritizing investments in manufacturing, clinical development, and commercial infrastructure to support growth areas like oncology, liver disease, HIV, and cell therapy.

- Total product sales (excl. Veklury) expected to grow 4% to 6% for base business in 2024, reaching $25.8 to $26.2 billion. - No change to 2024 revenue guidance; total product sales expected in $27.1 to $27.5 billion range. - HIV franchise expected to have roughly flat sales year-over-year in 2025 due to Medicare Part D redesign impact, but total business expected to grow overall. - Trodelvy sales are strong, exceeding $1 billion annually, with multiple ongoing Phase 3 trials aiming for label expansions in various cancers. - Cell therapy (Yescarta, Tecartus) poised for growth through expanding treatment centers, next-gen constructs, and new indications. - Seladelpar (from CymaBay acquisition) anticipated to contribute modestly in 2024, with more meaningful sales growth starting 2025 and beyond. - Continued phased clinical trials in HIV prevention and treatment with innovative long-acting regimens expected to drive growth. - Overall focus on disciplined expense management supports margin and earnings growth alongside top-line expansion.

- For 2024, Gilead expects total product sales of $27.1 to $27.5 billion, with base business growth of 4% to 6% excluding Veklury. - Diluted EPS guidance for 2024 is between $3.45 and $3.85, impacted by nondeductible CymaBay acquisition charges; excluding these charges, EPS aligns with prior guidance. - GAAP EPS for 2024 expected between $0.10 and $0.50. - Operating expenses are expected to decline mid-single-digit percentage versus 2023; SG&A to be modestly higher due to CymaBay expenses. - Effective tax rate for 2024 around 30%, including acquisition impacts. - HIV sales expected roughly flat in 2025 due to Medicare Part D redesign headwinds, but overall business anticipated to grow. - Operating margins projected to improve over time driven by revenue growth and disciplined expense management. - The CymaBay deal is dilutive in 2024 but expected to breakeven in 2025 and become accretive thereafter.

The transcript provided does not explicitly mention current or expected orderbook or pending orders for Gilead Sciences. However, relevant insights related to business outlook and sales include: - Total product sales, excluding Veklury, grew 6% year-over-year to $6.1 billion in Q1 2024. - HIV product sales grew 4% year-over-year; oncology product sales up 18%. - Seladelpar acquisition (CymaBay) is expected to contribute modestly in 2024 sales, more meaningfully in 2025 and beyond. - Near-term growth anticipated despite Medicare Part D redesign impacting HIV sales, which are expected to be flat in 2025. - Confidence expressed for returning to growth in cell therapy segment in the second half of 2024. - Upcoming regulatory approvals and data updates (e.g., for seladelpar, Trodelvy, lenacapavir) expected to support future sales momentum. No specific backlog or pending order numbers are disclosed in this excerpt.